The FDA approved Bravnetsa as the first radioligand therapy through the Abbreviated New Drug Application pathway, offering a bioequivalent alternative to Lutathera for adult patients with ...

Lyrfigtu (lirafugratinib) is approved for previously treated, unresectable, or metastatic FGFR2-altered cholangiocarcinoma based on data from the ReFocus trial.

HealthDay News — For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe, with more than one-third leading to ...

Eleven-point-four percent of patients who underwent liver transplantation for cirrhosis developed cirrhosis subsequent to transplant.

Topline phase 3 findings show the KIT receptor inhibitor barzolvolimab significantly reduced itch and hives while achieving high complete response rates in patients with chronic spontaneous urticaria.

The investigational mannose-1-phosphate replacement therapy aims to restore metabolic function and improve neurological outcomes in pediatric and adult patients.

Colonoscopy at 5 vs 3 years after polyp removal noninferior for colorectal cancer cumulative incidence at 5 years.

HealthDay News — Menopausal hormone therapy (MHT) initiation in perimenopausal or recently postmenopausal women with vasomotor symptoms may reduce cardiovascular disease (CVD) risk, with more ...

In the phase 3 OASIZ 301 trial, the investigational drug dazodalibep significantly reduced systemic disease activity in patients with moderate to severe Sjögren disease compared with placebo.

Estimated four-year event-free survival significantly higher in patients receiving blinatumomab vs traditional chemotherapy.

High amounts of egg and peanut during pregnancy and lactation do not result in lower risk for development of allergy in infants.

The kratom leaf contains only trace amounts of this compound naturally. Unlike kratom’s main ingredient, 7-OH acts directly on opioid receptors in the brain, so its effects can be stronger and more ...